ON
OncoZenge AB (publ)
ONCOZ.ST · STO
3.59 kr +12.36% (+0.40 kr)
1M -24.88%
Market Cap 50.4M kr
P/E Ratio -
Div. Yield -
ROE 2,775.09%
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/S 8.64x
EV/EBITDA N/A
P/B N/A
Growth
-
N/A Rev. growth N/A
FCF growth N/A
Book val. growth N/A
Profitability
20 /100
Weak Net margin 448.22%
Op. margin 435.65%
FCF margin 183.78%
Quality
6 /100
Poor ROE 2,775.09%
ROA 223.23%
Asset turnover 0.50x
Debt
3 /100
High Int. coverage -35.24x
Current ratio 0.51x
Net debt/EBITDA N/A
Stability
20 /100
Unstable EPS volatility 77.30%
Profitable years 0
Beta 1.31x
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o ONCOZ.ST
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Stian Kildal
Employees
1
Headquarters
Bromma